ATAI vs. GLUE

Last updated Aug 1, 2026

ATAI (Atai Life Sciences N.V.) and GLUE (Monte Rosa Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ATAI returned -14.26%/yr vs -7.59%/yr for GLUE. Their 0.37 correlation means their historical movements had little consistent relationship.

Performance

ATAI vs. GLUE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atai Life Sciences N.V. (ATAI) and Monte Rosa Therapeutics, Inc. (GLUE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ATAI achieves a 75.55% return, which is significantly higher than GLUE's 5.36% return.

ATAI

• 1D: 0.00%
• 1M: 38.34%
• 6M: 90.96%
• YTD: 75.55%
• 1Y: 72.18%
• 3Y*: 51.86%
• 5Y*: -14.26%
• 10Y*: —
• ALL TIME*: -18.92%

GLUE

• 1D: -27.16%
• 1M: -31.76%
• 6M: -19.49%
• YTD: 5.36%
• 1Y: 244.89%
• 3Y*: 33.78%
• 5Y*: -7.59%
• 10Y*: —
• ALL TIME*: -5.46%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
ATAI Atai Life Sciences N.V.	$95.05M	$137.83M	$67.37M
GLUE Monte Rosa Therapeutics, Inc.	$33.43M	$32.05M	$26.85M

ATAI vs. GLUE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ATAI Atai Life Sciences N.V.	75.55%	207.52%	-5.67%	-46.99%	-65.14%	-58.49%
GLUE Monte Rosa Therapeutics, Inc.	5.36%	125.94%	22.83%	-25.76%	-62.73%	-7.18%

Correlation

The correlation between ATAI and GLUE is 0.29, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.29
Correlation (3Y) Balances recent behavior with more history.	0.36
Correlation (5Y) Shows whether the relationship held over a longer period.	0.37
Correlation (All Time) Calculated using the full available price history since Jun 24, 2021	0.37

Fundamentals

Market Cap ATAI : $2.66B GLUE : $1.40B
EPS ATAI : -$2.50 GLUE : -$2.64
PS Ratio ATAI : 546.93 GLUE : 18.97
Total Revenue (TTM) ATAI : $3.49M GLUE : $42.95M
Gross Profit (TTM) ATAI : $3.49M GLUE : $34.56M
EBITDA (TTM) ATAI : -$663.38M GLUE : -$139.25M

Return for Risk

ATAI vs. GLUE — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ATAI

ATAI Risk / Return Rank: 74
ATAI Sharpe Ratio Rank: 74
ATAI Sortino Ratio Rank: 79
ATAI Omega Ratio Rank: 76
ATAI Calmar Ratio Rank: 74
ATAI Martin Ratio Rank: 68

GLUE

GLUE Risk / Return Rank: 95
GLUE Sharpe Ratio Rank: 95
GLUE Sortino Ratio Rank: 95
GLUE Omega Ratio Rank: 94
GLUE Calmar Ratio Rank: 96
GLUE Martin Ratio Rank: 94

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ATAI vs. GLUE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and Monte Rosa Therapeutics, Inc. (GLUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ATAI	GLUE	Difference
Sharpe ratio: Return per unit of total volatility	0.94	2.43	-1.49
Sortino ratio: Return per unit of downside risk	1.95	3.41	-1.46
Omega ratio: Gain probability vs. loss probability	1.23	1.44	-0.20
Calmar ratio: Return relative to maximum drawdown	1.57	5.62	-4.05
Martin ratio: Return relative to average drawdown	2.43	12.36	-9.93

ATAI vs. GLUE - Sharpe Ratio Comparison

The current ATAI Sharpe Ratio is 0.94, which is lower than the GLUE Sharpe Ratio of 2.43. The chart below compares the historical Sharpe Ratios of ATAI and GLUE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ATAI vs. GLUE - Drawdown Comparison

The maximum ATAI drawdown since its inception was -95.05%, roughly equal to the maximum GLUE drawdown of -94.08%. Use the drawdown chart below to compare losses from any high point for ATAI and GLUE.

Drawdown Indicators

	ATAI	GLUE	Difference
Max Drawdown Largest peak-to-trough decline	-95.05%	-94.08%	-0.97%
Max Drawdown (1Y) Largest decline over 1 year	-48.06%	-41.84%	-6.22%
Max Drawdown (3Y) Largest decline over 3 years	-59.23%	-64.29%	+5.06%
Max Drawdown (5Y) Largest decline over 5 years	-94.17%	-94.08%	-0.09%
Current Drawdown Current decline from peak	-65.81%	-60.86%	-4.95%
Average Drawdown Average peak-to-trough decline	-80.58%	-73.78%	-6.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.99%	19.05%	+11.94%

Volatility

ATAI vs. GLUE - Volatility Comparison

Atai Life Sciences N.V. (ATAI) and Monte Rosa Therapeutics, Inc. (GLUE) have volatilities of 33.68% and 35.38%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ATAI	GLUE	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.68%	35.38%	-1.70%
Volatility (6M) Calculated over the trailing 6-month period	61.09%	49.79%	+11.30%
Volatility (1Y) Calculated over the trailing 1-year period	82.57%	97.54%	-14.97%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.28%	101.44%	-16.16%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	84.88%	100.99%	-16.11%

Dividends

ATAI vs. GLUE - Dividend Comparison

Neither ATAI nor GLUE has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ATAI and GLUE in my portfolio?

ATAI and GLUE have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ATAI or GLUE?

GLUE has higher volatility (35.38%) compared to ATAI (33.68%). In terms of maximum drawdown, ATAI dropped -95.05% vs GLUE's -94.08%.

Which has better risk-adjusted returns?

GLUE currently has the higher Sharpe Ratio (2.43 vs 0.94), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.